{"schema_version":"1","generated_at":"2026-10-30T05:20:22.487Z","data_as_of":null,"url":"https://www.findmykol.com/kol/abdullah-ladha","json_url":"https://www.findmykol.com/kol/abdullah-ladha/profile.json","record_kind":"basic","profile_kind":"clinical","person":{"slug":"abdullah-ladha","name":"Abdullah Ladha","credential":"MD","specialty":"Hematology","specialty_raw":"Hematology","therapeutic_area":"Hematology","therapeutic_areas":["Hematology"],"city":"Scottsdale","state":"AZ","region":{"label":"West","url":"https://www.findmykol.com/region/west"}},"identifiers":{"npi":"1033341672","orcid":"0009-0006-9598-6467","openalex":"A5081406081"},"summary":"Abdullah Ladha is a Hematology physician. OpenAlex indexes 95 publications with 363 citations (h-index 10).","overview":null,"focus":{"indications":[],"research_topics":["Hematology"]},"scholarship":{"works_count":95,"cited_by_count":363,"h_index":10,"latest_activity_year":2025,"source":"works"},"payments":{"company_count":24,"program_years":{"first":2021,"last":null},"rows_total":41,"shown":3,"withheld":38,"rows":[{"payer":"Syndax Pharmaceuticals, Inc.","program_year":2025,"amount_usd":11446.43,"payment_count":8,"source_url":"https://openpaymentsdata.cms.gov/search?query=1033341672"},{"payer":"PFIZER INC.","program_year":2025,"amount_usd":2514.59,"payment_count":2,"source_url":"https://openpaymentsdata.cms.gov/search?query=1033341672"},{"payer":"ABBVIE INC.","program_year":2025,"amount_usd":44.39,"payment_count":2,"source_url":"https://openpaymentsdata.cms.gov/search?query=1033341672"}],"record_url":"https://openpaymentsdata.cms.gov/search?query=1033341672","source":"payments"},"prescribing":{"data_year":2024,"areas_total":4,"areas_shown":3,"areas":[{"area":"Cancer & immunology","share_pct":49.4,"classes_total":2,"classes":[{"class":"Kinase inhibitor","setting":"prescribed","share_pct":34.6,"drugs":[{"name":"Brukinsa","share_pct":37.5},{"name":"Kisqali","share_pct":21.4},{"name":"Ibrance","share_pct":21.4},{"name":"Tasigna","share_pct":19.6}],"max_beneficiaries":null},{"class":"Aromatase Inhibitor","setting":"prescribed","share_pct":14.8,"drugs":[{"name":"Anastrozole","share_pct":54.2},{"name":"Letrozole","share_pct":45.8}],"max_beneficiaries":null}]},{"area":"Dermatology","share_pct":34,"classes_total":2,"classes":[{"class":"Herpesvirus Nucleoside Analog DNA Polymerase Inhibitor","setting":"prescribed","share_pct":25.3,"drugs":[{"name":"Acyclovir","share_pct":100}],"max_beneficiaries":12},{"class":"Corticosteroid","setting":"prescribed","share_pct":8.6,"drugs":[{"name":"Triamcinolone Acetonide","share_pct":100}],"max_beneficiaries":null}]},{"area":"Anti-infectives","share_pct":8.6,"classes_total":1,"classes":[{"class":"Short-acting sulfonamides","setting":"prescribed","share_pct":8.6,"drugs":[{"name":"Sulfamethoxazole-Trimethoprim","share_pct":100}],"max_beneficiaries":null}]}],"care_setting":{"dominant":"facility","data_year":2024,"office_pct":16.8,"facility_pct":83.2},"source":"medicare"},"publications":{"total":50,"shown":5,"withheld":45,"matched_by":"OpenAlex author record","recent":[{"title":"Real-world outcomes for young adult patients receiving CD19 CAR T-cell therapy","year":2025,"journal":"Blood Advances","source_url":"https://doi.org/10.1182/bloodadvances.2024014846","status":"verified"},{"title":"CAR HEMATOTOX independently predicts outcomes after CD19 CAR-T therapy for acute lymphoblastic leukemia","year":2025,"journal":"Blood Advances","source_url":"https://doi.org/10.1182/bloodadvances.2025017526","status":"verified"},{"title":"Real-world toxicity of brexucabtagene autoleucel in adults with relapsed/refractory B-cell acute lymphoblastic leukemia","year":2025,"journal":"Blood Immunology & Cellular Therapy","source_url":"https://doi.org/10.1016/j.bict.2025.100028","status":"verified"},{"title":"The impact of social determinants of health on outcomes of brexucabtagene autoleucel in adults with relapsed/refractory B-cell acute lymphoblastic leukemia","year":2025,"journal":"Bone Marrow Transplantation","source_url":"https://doi.org/10.1038/s41409-025-02693-0","status":"verified"},{"title":"Tyrosine Kinase Inhibitor (TKI) Maintenance Improves Remission Durability in Philadelphia-Chromosome Acute Lymphoblastic Leukemia (Ph+ ALL) Following Brexucabtagene Autoleucel (Brexu-cel)","year":2025,"journal":"Biology of Blood and Marrow Transplantation","source_url":"https://doi.org/10.1016/j.jtct.2025.01.187","status":"verified"}],"source":"works"},"contact":{"address_1":"10460 N 92ND ST STE 300","city":"Scottsdale","state":"AZ","zip":"852584547","phone":"480-323-1573","source_url":"https://npiregistry.cms.hhs.gov/provider-view/1033341672","source":"identity"},"similar":[{"name":"Joseph Antin","slug":"joseph-antin","institution":"Harvard University","specialty":"Hematology","url":"https://www.findmykol.com/kol/joseph-antin","json_url":"https://www.findmykol.com/kol/joseph-antin/profile.json"},{"name":"Scott Kaufmann","slug":"scott-kaufmann","institution":"Mayo Clinic College of Medicine","specialty":"Hematology","url":"https://www.findmykol.com/kol/scott-kaufmann","json_url":"https://www.findmykol.com/kol/scott-kaufmann/profile.json"},{"name":"Jeffrey Miller","slug":"jeffrey-miller","institution":"University of Minnesota Medical School","specialty":"Hematology","url":"https://www.findmykol.com/kol/jeffrey-miller","json_url":"https://www.findmykol.com/kol/jeffrey-miller/profile.json"},{"name":"Ruben Mesa","slug":"ruben-mesa","institution":"Atrium Health Wake Forest Baptist Comprehensive Cancer Center","specialty":"Hematology","url":"https://www.findmykol.com/kol/ruben-mesa","json_url":"https://www.findmykol.com/kol/ruben-mesa/profile.json"}],"coverage":{"note":"A basic record from the physician directory. Sections absent here were not yet checked for this person, so absence means not yet looked, never none found.","not_yet_checked":["funding","congress","network","presence","recognition"]},"not_included":{"note":"This document is the public layer: neutral facts cited to their source. Judgments (influence tier, archetype, trajectory commentary) and the itemized rows past each section's public teaser are account features and are not served here or to crawlers.","withheld_rows":{"payments":38,"publications":45}},"sources":{"orcid":{"name":"ORCID","url":"https://orcid.org","provides":"The verified researcher identity that anchors authorship"},"identity":{"name":"NPPES (CMS)","url":"https://npiregistry.cms.hhs.gov","provides":"Identity, specialty and practice location for every U.S. clinician","coverage":"Practice location (not mailing) from the NPPES record","record_last_updated":"2025-05-12","provider_certified":"2025-05-12","collected_at":"2026-10-27T00:00:00.000Z"},"works":{"name":"OpenAlex","url":"https://openalex.org","provides":"Citations, h-index, research topics, most-cited works and congress abstracts"},"payments":{"name":"CMS Open Payments","url":"https://openpaymentsdata.cms.gov","provides":"Industry payments reported to CMS, by company and program year","disclaimer":"Payments are publicly reported to CMS. Their existence does not imply wrongdoing; CMS does not interpret these data.","coverage":"Program years 2021 onward"},"medicare":{"name":"CMS Medicare Part D Prescribers and Part B","url":"https://data.cms.gov/provider-summary-by-type-of-service","provides":"Share of this prescriber's Medicare fee-for-service prescribing by drug class and therapeutic area, classified with WHO ATC and NLM RxClass","disclaimer":"Proportions of the prescriber's own classified prescribing, never patient counts or dollar amounts. Fee-for-service only; CMS publishes about 17 months after the fact and suppresses counts of ten patients or fewer.","data_year":2024}},"methodology_url":"https://www.findmykol.com/about#methodology"}